The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARAY | -9.04% | -48.06% | -12.28% | -94% |
| S&P | +15.06% | +95.03% | +14.29% | +365% |
Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.
The company released its fiscal 2023 third-quarter numbers after the bell Wednesday.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $127.54M | -5.0% |
| Gross Profit | $38.98M | 1.4% |
| Gross Margin | 30.56% | 1.9% |
| Market Cap | $141.13M | -21.9% |
| Market Cap / Employee | $0.14M | 0.0% |
| Employees | 990 | 0.3% |
| Net Income | $1.12M | -66.8% |
| EBITDA | $5.83M | -29.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $57.99M | -16.0% |
| Accounts Receivable | $83.48M | -9.6% |
| Inventory | 141 | 1.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $156.27M | -20.6% |
| Short Term Debt | $20.11M | 43.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.34% | 2.9% |
| Return On Invested Capital | -2.70% | 0.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.03M | -217.1% |
| Operating Free Cash Flow | -$9.71M | -198.2% |
| Metric | Q1 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 303.39 | - | |||
| Price to Book | 4.00 | 4.40 | 3.84 | 2.84 | -35.37% |
| Price to Sales | 0.41 | 0.45 | 0.40 | 0.33 | -20.98% |
| Price to Tangible Book Value | -14.31 | -15.74 | -18.80 | -8.38 | -22.65% |
| Price to Free Cash Flow TTM | 36.21 | 9.67 | - | ||
| Enterprise Value to EBITDA | -481.03 | 57.06 | 121.89 | 45.88 | 17.30% |
| Free Cash Flow Yield | 2.8% | 10.3% | - | ||
| Return on Equity | -34.4% | -9.2% | 1.5% | -2.5% | -92.00% |
| Total Debt | $208.79M | $213.49M | $214.37M | $176.38M | -16.31% |
ARAY earnings call for the period ending June 30, 2022.
ARAY earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
